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Deep brain stimulation (DBS) is an estab-
lished treatment for Parkinson’s disease 
(PD) patients who present with disabling 
motor complications, such as fluctuations 
and dyskinesias unmanageable by medi-
cal treatment alone (The Deep-Brain 
Stimulation for Parkinson’s Disease Study 
Group, 2001). In recent years, two main tar-
gets have emerged: the subthalamic nucleus 
(STN) and the globus pallidum internum 
(GPi). These brain nuclei differ signifi-
cantly for anatomical connections, size, 
and functional role within the basal ganglia. 
The available clinical experience, arising 
either from mono-center or multi-center 
studies, is more detailed for STN com-
pared to GPi DBS. First, short-term data 
have shown that, compared to best medical 
treatment, STN stimulation is more effi-
cacious for controlling dyskinesias, motor 
function, and quality of life, but is associ-
ated with a higher risk of serious adverse 
events (Deuschl et al., 2006). Furthermore, 
long-term sustained motor efficacy of STN 
implants has been demonstrated for up to 
8 years now (Fasano et al., 2010), compared 
to 5.5 years of GPi (Moro et al., 2010b). 
Medication- and stimulation-resistant 
symptoms, mainly axial signs (such as gait 
and postural impairment) become evident 
after 5 years after STN implants. These fea-
tures are likely due to disease progression, 
which also require either the increase of 
dopaminergic medication dosage or of the 
total electrical energy delivered to the STN 
(Fasano et al., 2010).
Three recent studies (two randomized 
and one uncontrolled) have compared 
the effects of STN and GPi stimulation in 
complicated PD patients (Table 1). Taken 
together, they indicate that STN and GPi 
stimulations have similarities and differ-
ences. They both improve motor signs of 
PD and reduce dyskinesias; however, STN 
stimulation generates more pronounced 
motor improvement allowing to reduce 
dopaminergic medication to a higher 
degree. The trade-off is a higher incidence 
of treatment-related adverse events, in 
particular speech disturbances and post-
operative confusion, in patients receiving 
STN implants. These trials have intrinsic 
methodological limitations that curb their 
external validity, particularly due to the 
multi-center design with heterogeneity of 
targeting techniques, equipment, selection 
criteria, and post-operative procedures. 
Currently, most centers in Europe and 
in North America perform implants in 
the STN rather than in the GPi; in most 
instances, this preference is based on the 
team experience. Recent data indicate, 
however, that target selection could be tai-
lored to the patient’s clinical and personal 
profile: GPi DBS may suit better patients 
with dose-limiting dyskinesias or behavio-
ral and cognitive issues, whereas STN DBS 
may be more indicated for younger patients 
with prominent akinesia and tremor or with 
behavioral disorders related to dopaminer-
gic medication.
Non-motor features may provide predic-
tive information on long-term STN DBS 
efficacy. A recent prospective study showed 
that the occurrence of REM sleep behavior 
disorder in PD patients undergoing STN 
DBS may be per se associated with a less 
favorable outcome and a more prominent 
development of axial symptoms over time 
(Zibetti et al., 2010); by contrast, cardiovas-
cular dysautonomia is compatible with sat-
isfactory motor outcome, as reported 1 year 
after STN DBS (Holmberg et al., 2005).
The observation of a decay of motor 
outcome 8 year after STN implants (Fasano 
et al., 2010) raises the issue whether sur-
gery should be considered an earlier 
therapeutic option, being also performed 
on patients with uncomplicated PD. The 
rationale would be to maximize motor 
benefit and spare dopaminergic medica-
tion before disability accumulates and the 
quality of personal and social life decays. 
Most implanting centers apply patients 
selection criteria stated by the CAPSIT-PD 
Table 1 | Published data comparing bilateral GPi and STN implants in PD.
  GPi STN Reference 
  stimulation stimulation
MoToR STaTuS
UPDRS motor change at 1 year  -39%§  -48%§  Anderson et al. (2005)
UPDRS motor change at 2–4 years  -43.8%§  -53.9%§  Moro et al. (2010b)
  -28.2%§  -25.3%§  Follett et al. (2010)
UPDRS motor change at 5–6 years  -37 .1%§  -50.4%§  Moro et al. (2010b)
FuNcTioNal STaTuS
UPDRS activities of daily living at last FU  0.0%  0.0%  Anderson et al. (2005)
  22.4%§ 64.7%§  Moro et al. (2010b)
  -17 .2%  -11.5%  Follett et al. (2010)
TReaTMeNT STaTuS
LEDD change at last FU  -3%  -38%§  Anderson et al. (2005)
  -22.6%  -55.9%§  Moro et al. (2010b)
  -243 mg§  -408 mg§  Follett et al. (2010)
UPDRS motor change was evaluated with stimulation turned on, but without antiparkinsonian medication; 
UPDRS activities of daily living was evaluated with stimulation turned on and with antiparkinsonian medica-
tions. §Pre-operative and post-operative comparison statistically significant; LEDD, levodopa-equivalent daily 
dose. Negative data indicate improvement or medication reduction, positive data indicate the opposite.
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to motor context and movement needs, a 
physiological function that cannot be pro-
vided by medication.
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develop after DBS, or otherwise improve, 
persist, or worsen (Bandini et al., 2007; Lim 
et al., 2009). The main issue to solve is what 
factors allow predicting behavioral varia-
tions after implants. A likely hypothesis is 
that medication or DBS may differentially 
affect some preexisting personality features; 
medication dosage and stimulation settings 
may represent key variables of outcome. 
There is also evidence that STN DBS causes 
executive inhibitory deficits and impulsive 
behavior under high-conflict conditions; 
these phenomena are probably due to an 
impulsive decision-making that may be 
explained by an inability to self-modulate 
decision times as a function of conflict 
(Frank et al., 2007). STN DBS may act 
directly on the gating mechanism involved 
in response initiation and proactive inhibi-
tory commands (Ballanger et al., 2009).It is 
not known whether these phenomena are 
affected by patients’ age or disease duration.
In recent years, other potential targets 
for PD have been investigated. Experimental 
findings suggest that low frequency DBS 
of the pedunculopontine nucleus (PPN) 
could improve some of the axial symp-
toms of the disease unresponsive to STN 
DBS and dopaminergic therapy, particu-
larly freezing of gait and the frequency of 
falls (Moro et al., 2010a), but the results 
of a recent double-blind cross-over study 
(Ferraye et al., 2010) have frozen expecta-
tions. Simultaneous STN and PPN stimula-
tion has also been performed with the aim 
to provide better motor control to patients 
(Stefani et al., 2007). New devices will allow 
controlling four or more electrodes, allow-
ing to perform simultaneous multiple tar-
get stimulation with just one implantable 
pulse generator.
The most expected innovation, however, 
is technical. In order to optimize the efficacy 
of DBS and reduce unwanted current spread 
to adjacent brain structures, electrodes need 
to be redesigned and active contacts should 
have improved geometry. Nanotechnology 
will permit a progressive miniaturization 
of hardware components and ideally the 
improvement of lengthy connecting cables 
and distant pulse generators. The develop-
ment of sensor-driven pacing has been a 
landmark innovation for cardiac pacemak-
ers, enabling the device to respond to physi-
ologic demands. Similarly, the development 
of responsive DBS stimulators, would allow 
moving beyond the current paradigms of 
 committee  (Defer et al., 1999) that recom-
mend to select patients with at least 5 years 
of disease duration, with significant motor 
disability and no cognitive or psychiatric 
impairment. No recommendation is availa-
ble on age or disease duration limits for STN 
or GPi implants. The few studies addressing 
the effects of age or disease duration at time 
of implant proved to be inconclusive. An 
uncontrolled study has identified age and 
pre-operative levodopa responsiveness and, 
to a lesser extent, disease duration, as pre-
dictors of outcome for bilateral STN DBS 
(Charles et al., 2002). This was not con-
firmed by a systematic review that found 
no evidence of better surgical outcome in 
younger patients who received STN DBS 
(Kleiner-Fisman et al., 2006). More recently, 
it has been agreed that the overall motor 
improvement is unrelated to age at time 
of implant (Derost et al., 2007), although 
quality of life improvements occur only in 
younger patients.
The question as to when is the optimal 
timing for DBS implants remains very con-
crete. An 18-month prospective trial signifi-
cantly favored early DBS over early medical 
therapy alone in measures of quality of life, 
motor performance without medication, 
levodopa-induced motor complications, 
and medication reduction (Schupbach 
et al., 2007). The adverse events were mild 
or transient, and overall psychiatric mor-
bidity and anxiety improved more in the 
surgical group. This study suggested that 
treating younger patients before symp-
toms become disabling should help many 
remain productive longer than without sur-
gery, making surgery an ethically acceptable 
option for younger, less severely compro-
mised patients. Two randomized controlled 
trials aimed at assessing the usefulness of 
early STN DBS are currently underway: the 
EARLYSTIM multi-center German–French 
study (ClinicalTrials.gov NCT00354133) 
and the North American mono-center 
study (ClinicalTrials.gov NCT00282152). 
The results of these trials are expected not 
before a couple of years.
A reason for performing STN implants 
earlier also stems by the aim to prevent the 
occurrence of a dopaminergic dysregula-
tion syndrome. Data regarding the effect 
of STN DBS on dopamine dysregulation, 
impulse control disorders, and punding in 
PD are still limited and conflicting: available 
observations report that these features may 
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